Merck & Company, Inc. stock stays bullish as melanoma vaccine trial clears Phase 3
Covered by 1 source · 1 article
Merck & Company, Inc. stock shows a clear split between timeframes. The daily chart remains firmly bullish, while shorter timeframes reveal cooling momentum. Fresh clinical news from the Merck-Moderna melanoma vaccine program adds another l…
Covered by
